RxDoctor Payments Data

Tarun Narang, MD

Gastroenterology · Charlotte, NCNPI 1205904448

Payments from drug & device makers

$11,337in general payments, 2019–2025

Across 673 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$948
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$852
  • Bristol Myers Squibb$672
  • Pfizer$554
  • plus $4K from 41 others

What the payments were for

  • Travel & lodging$130%
  • Food & beverage$11,26199%
  • Education$631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,337 in reported general payments places this provider in the 75th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$324,782
Medicare patients
566
Services billed
3,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase59$241,971
Humira PenAdalimumab14$97,412
ZenpepLipase/Protease/Amylase16$71,345
LinzessLinaclotide31$41,581
XifaxanRifaximin15$34,724
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates171$11,448
Dexlansoprazole DrDexlansoprazole20$7,271
SutabSod Sulf/Pot Chloride/Mag Sulf42$6,817
Mesalamine ErMesalamine19$5,470
Ursodiol27$3,462
Omeprazole186$3,015
Pantoprazole Sodium176$2,626
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C17$2,400
Balsalazide Disodium11$2,044
Famotidine69$1,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,721$283,55190 claims
Aimmune Therapeutics, Inc.Zenpep$179$71,34516 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$852$37,12432 claims
Braintree Laboratories, Inc.Sutab$87$6,81742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →